MONSANTO TECHNOLOGY LLC v. E.I. DUPONT DE NEMOURS
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Federal Circuit Summary
Before Dyk, Reyna, and Wallach. Appeal from the Patent Trial and Appeal Board.
Summary: Extrinsic evidence can be used to find that an allegedly anticipating reference necessarily includes relevant claim limitations.
E.I. DuPont de Nemours & Co. (“DuPont”) sought inter partes reexamination of a patent owned by Monsanto Technology LLC (“Monsanto”). During the inter partes reexamination, DuPont submitted two declarations from a named inventor of an allegedly anticipating prior art reference. Relying on the declarations, the PTAB found that the prior art reference “necessarily includes” certain claim limitations of Monsanto’s patent. Accordingly, the PTAB found that certain claims of Monsanto’s patent were anticipated.
Appealing to the Federal Circuit, Monsanto argued that the PTAB erred by relying on the declarations to reject the asserted claims for anticipation, which Monsanto argued contained secret and non-prior art data.
The Federal Circuit affirmed the PTAB’s decision. Relying on the declarations, the Federal Circuit held that substantial evidence demonstrates that the prior art reference inherently anticipates the asserted claims. In response to Monsanto’s argument that the declarations did not qualify as prior art, the Federal Circuit explained that “[e]xtrinsic evidence may be used to interpret the allegedly anticipating reference.” Next, in response to Monsanto’s argument that the declarations were “secret data” because they were not published, the Federal Circuit explained that the declarations were offered in support of the prior art already of record and that such reliance on extrinsic evidence is proper in an inherency analysis.
This case is: MONSANTO TECHNOLOGY LLC v. E.I. DUPONT DE NEMOURS
Written By: Andrea Cheek and Thomas Woodland
Edited By: Paul Stewart
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…